<DOC>
	<DOCNO>NCT02478112</DOCNO>
	<brief_summary>The benefit dose escalation radiotherapy ( RT ) biochemical control prostate cancer clearly establish fact base result different publish prospective trial . This benefit , acquire three-dimensional conformal radiation technique counterbalance increase urinary gastrointestinal toxicity . The joint progress dose plan system multileaf collimator ( MLC ) technology enable Intensity Modulated Radiation Therapy ( IMRT ) . Recently contribution `` spacers '' position septum rectum prostate could improve functional result IMRT term rectal toxicity . The aim investigator study assess dosimetric gain contribution implantable BioProtect balloon organ risk .</brief_summary>
	<brief_title>Use Biodegradable Balloon Treatment Prostate Cancer Intensity Modulated Radiotherapy ( BioPro-RCMI )</brief_title>
	<detailed_description>Patients eligible trial sign consent participate undergo scan verify possibility implantation balloon . Before implantation balloon , dosimetric scan perform . Radiotherapy administer accord habit centre : Intensity modulate radiotherapy : 2 Gy / session , 5 weekly session , total dose 74-80 Gy ( +/- associate hormone therapy ) . Patients clinical examination : - prior start treatment - week radiotherapy - end radiotherapy - end study . They also complete quality life questionnaire : - prior start treatment - mid-treatment - end radiotherapy - 3 , 6 , 12 24 month end radiotherapy . Finally , patient undergo laboratory examination : - prior start treatment - 3 month end radiotherapy - every 6 month .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>1 . Patient 18 year old 2 . With localized adenocarcinoma prostate intermediate risk D'AMICO stage MRI &lt; T3 3 . Requiring treatment Intensity Modulated Radiotherapy 4 . PSA ( ProstateSpecific Antigen ) level ≤ 20 ng/mL external beam radiotherapy 5 . Prostate volume &gt; 15 cc 6 . Short hormone therapy possibly associate ( 46 month ) 7 . Patient without clinical sign progressive disease ( Performing bone scan CT scan optional ) 8 . Performance status ECOG ( Eastern Cooperative Oncology Group ) ≤ 1 9 . Life expectancy ≥ 10 year 10 . Informed consent sign 1 . Incompatibility implantation Bioprotect balloon : ongoing anticoagulant vitamin K antagonist ( VKA ) heparintherapy patient immunosuppression serious chronic disease heart failure , cirrhosis , chronic kidney failure , colic rectal digestive inflammatory disease history prostatitis lower gastrointestinal infection treat ongoing history rectocolic inflammatory disease repeat prostatic resection untreated perineal wound 2 . Prior treatment hormone therapy 3 . History another invasive cancer within 5 year prior study entry ( exception treat basal cell skin carcinoma ) 4 . History pelvic radiotherapy 5 . Severe hypertension non control adapt treatment ( ≥ 160 mm Hg systole and/or ≥ 90 mm Hg diastole ) 6 . Ongoing antineoplastic therapy 7 . Person deprive liberty tutorship 8 . Inability submit medical monitoring study geographical , social psychological reason . 9 . Conformal radiotherapy without intensity modulation</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Intensity Modulated Radiotherapy</keyword>
	<keyword>Balloon implant</keyword>
</DOC>